Geode Capital Management LLC Acquires 30,826 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Geode Capital Management LLC raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,875,540 shares of the biopharmaceutical company’s stock after acquiring an additional 30,826 shares during the quarter. Geode Capital Management LLC owned approximately 1.73% of ACADIA Pharmaceuticals worth $44,234,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ACAD. Marshall Wace LLP increased its holdings in ACADIA Pharmaceuticals by 431.1% in the second quarter. Marshall Wace LLP now owns 2,774,353 shares of the biopharmaceutical company’s stock valued at $45,083,000 after purchasing an additional 2,251,940 shares during the period. Millennium Management LLC grew its position in shares of ACADIA Pharmaceuticals by 36.2% in the 2nd quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company’s stock valued at $47,738,000 after buying an additional 781,070 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of ACADIA Pharmaceuticals in the third quarter valued at about $11,535,000. Dimensional Fund Advisors LP bought a new position in shares of ACADIA Pharmaceuticals during the second quarter worth about $10,550,000. Finally, Eventide Asset Management LLC bought a new stake in ACADIA Pharmaceuticals in the third quarter valued at approximately $8,882,000. Institutional investors own 96.71% of the company’s stock.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,073 shares of ACADIA Pharmaceuticals stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. The trade was a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Brendan Teehan sold 10,329 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $173,630.49. Following the completion of the sale, the chief operating officer now owns 62,105 shares of the company’s stock, valued at approximately $1,043,985.05. This represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,661 shares of company stock valued at $414,551 over the last 90 days. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Trading Up 1.8 %

ACADIA Pharmaceuticals stock opened at $17.17 on Tuesday. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of 22.01 and a beta of 0.40. The firm’s fifty day moving average price is $16.29 and its two-hundred day moving average price is $16.25. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $31.93.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.06. The business had revenue of $250.40 million for the quarter, compared to analysts’ expectations of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) EPS. On average, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ACAD shares. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, StockNews.com lowered ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $25.60.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.